Elusys Therapeutics, Inc.
Jeremy Middleton is the current Chief Executive Officer of AJK Biopharmaceutical since October 2022. He also serves as the President of Elinic, LLC since May 2007. With a background in leading corporate development projects in the life sciences industry, he has extensive experience in strategic planning, M&A activities, and securing funding. Previous roles include VP Corporate Development at a biotech company focused on monoclonal antibody therapeutics and VP Business Development at Valera Pharmaceuticals. Prior to that, he held leadership positions at Neose Technologies, Inc. and Abbott Laboratories/BASF Pharma. Middleton's educational background includes a Bachelor of Science in Applied Chemistry from De Montfort University.
This person is not in any teams
This person is not in any offices
Elusys Therapeutics, Inc.
Elusys Therapeutics is dedicated to delivering innovative medical countermeasures that enable fast, effective, and durable protection against infectious agents. Our goal is to accelerate the development and commercialization of novel biodefense solutions, such as our anthrax antitoxin ANTHIM® (obiltoxaximab), for strategic government partners.